Neal D. Shore, MD, FACS - Advancing the Management of Urothelial Cancer With Immuno-Oncology and Targeted Approaches: Key Concepts for Urology Professionals on the Front Lines of Care

Go online to PeerView.com/XNW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of advanced urothelial carcinoma of the bladder has undergone significant transformation in the last 2 years, with the emergence of immune checkpoint inhibitors as an essential component of the treatment armamentarium. Extensive research is also focused on newer approaches, such as antibody-drug conjugates and FGFR inhibitors, against actionable targets on urothelial cancer cells. This rapid expansion in the field poses several challenges for urologists and other healthcare professionals who are essential to the multidisciplinary team managing patients with urothelial cancer. In this PeerView activity, based on a recent live symposium, a panel of bladder cancer experts review the science and latest evidence on immunotherapeutic and targeted strategies for urothelial cancers combined with practical, interactive segments offering the urologist’s perspective on achieving optimal outcomes through appropriate counseling of patients and effective collaboration among different specialists, including urologists and oncologists. Upon completion of this activity, participants should be better able to: Describe the rationale for and mechanisms of action of novel immunotherapeutic and targeted strategies in clinical development for management of urothelial cancer, Discuss the latest evidence on and clinical roles of approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors throughout the urothelial cancer disease continuum, Employ effective strategies to ensure optimal and timely application of the latest treatment approaches for patients with urothelial cancer, including in the context of clinical trial enrollment, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with novel therapies for urothelial cancer.